VERX
Vertex, Inc.
$13.44
+0.27
(+2.05%)
Mkt Cap
2.17B
Volume
730,203
52W Range
10.59-42.44
Sector
Technology
Beta
0.80
EPS (TTM)
-0.03
P/E Ratio
399.40
Revenue (TTM)
768.03M
Rev Growth (5Y)
+14.8%
EPS Growth (5Y)
N/A
Company Description
Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 748.44M | 666.78M | 572.39M | 491.62M | 425.55M | 374.67M | 321.50M | 272.40M |
| Net Income | 7.21M | (52.73M) | (13.09M) | (12.30M) | (1.48M) | (75.08M) | 31.06M | (6.11M) |
| EPS | 0.05 | -0.34 | -0.09 | -0.08 | -0.01 | -0.60 | 0.21 | -0.05 |
| Free Cash Flow | 69.31M | 99.05M | 6.10M | 3.43M | 46.92M | 26.74M | 54.94M | 47.13M |
| FCF / Share | 0.48 | 0.64 | 0.04 | 0.02 | 0.32 | 0.20 | 0.38 | 0.38 |
| Operating CF | 165.54M | 164.82M | 74.33M | 63.85M | 90.29M | 59.54M | 92.50M | 80.45M |
| Total Assets | 1.27B | 1.17B | 759.93M | 719.19M | 670.21M | 558.78M | 264.62M | 215.07M |
| Total Debt | 359.62M | 351.89M | 66.97M | 73.52M | 28.61M | 1.11M | 51.49M | 54.88M |
| Cash & Equiv | 314.01M | 296.05M | 68.17M | 91.80M | 73.33M | 303.05M | 75.90M | 55.84M |
| Book Value | 258.92M | 179.35M | 252.98M | 229.72M | 230.08M | 229.34M | (112.43M) | (111.70M) |
| Return on Equity | 0.03 | -0.29 | -0.05 | -0.05 | -0.01 | -0.33 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 196.65M | 194.71M | 192.11M | 184.56M | 177.06M | 178.46M | 170.44M | 161.10M | 156.78M | 154.91M | 145.03M | 139.69M |
| Net Income | (2.51M) | (7.00M) | 4.04M | (961,000) | 11.13M | (67.80M) | 7.22M | 5.16M | 2.68M | 15.33M | (3.40M) | (6.90M) |
| EPS | -0.01 | -0.04 | 0.03 | -0.01 | 0.07 | -0.43 | 0.05 | 0.03 | 0.02 | 0.10 | -0.02 | -0.05 |
| Free Cash Flow | 13.31M | 19.70M | 36.03M | 30.15M | (12.25M) | 17.90M | 18.36M | 31.14M | 4.50M | 28.84M | 9.05M | (21.23M) |
| FCF / Share | 0.08 | 0.11 | 0.22 | 0.19 | -0.08 | 0.11 | 0.12 | 0.18 | 0.03 | 0.19 | 0.06 | -0.14 |
| Operating CF | 37.98M | 46.59M | 62.47M | 46.00M | 14.80M | 41.13M | 41.40M | 46.44M | 24.57M | 47.64M | 27.59M | (4.39M) |
| Total Assets | 1.21B | 1.27B | 1.22B | 1.20B | 1.15B | 1.17B | 1.19B | 1.02B | 755.80M | 759.93M | 720.07M | 725.07M |
| Total Debt | 350.14M | 359.62M | 351.37M | 351.89M | 351.37M | 351.89M | 352.19M | 352.41M | 65.22M | 66.97M | 69.16M | 70.82M |
| Cash & Equiv | 252.46M | 314.01M | 313.51M | 284.39M | 270.39M | 296.05M | 278.98M | 325.54M | 56.13M | 68.17M | 49.50M | 41.87M |
| Book Value | 246.50M | 258.92M | 264.47M | 248.04M | 200.49M | 179.35M | 259.03M | 233.13M | 250.13M | 252.98M | 220.17M | 225.72M |
| Return on Equity | -0.01 | -0.03 | 0.02 | -0.00 | 0.06 | -0.38 | 0.03 | 0.02 | 0.01 | 0.06 | -0.02 | -0.03 |
VERX News
New Vertex Research Highlights Rising Revenue Risk from IT, Tax, and Finance Misalignment
Vertex Q1 Earnings Call Highlights
Vertex: Profitability Ramps Up As Company Drives Efficiency Initiatives
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics
Vertex (VERX) Tops Q1 Earnings and Revenue Estimates
Vertex Announces First Quarter 2026 Financial Results
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings